^
Association details:
| Biomarker: | MYCN amplification |
|---|---|
| Cancer: | Neuroblastoma |
| Drug: | Farydak (panobinostat) (HDAC inhibitor) + GSK2816126 (EZH2 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
CRISPR-Cas9 screen reveals a MYCN-amplified neuroblastoma dependency on EZH2
Excerpt:
...synergy of GSK126 and panobinostat is strong across a broad concentration range in all 4 of the MYCN-amplified neuroblastoma cell lines tested…the HDAC inhibitor panobinostat scored as the most synergistic with GSK126...
DOI:
10.1172/JCI90793
